Drugs reduce bone cancer damage but clinical guidance remains non-specific

May 15, 2012

Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma.

Multiple myeloma is a type of cancer that grows in and on bones, and can cause fractures in long bones and the spine. Severe back pain is a common symptom. Bisphosphonate drugs may help to reduce the occurrence of fractures and bone pain in myeloma patients. They work by inhibiting the activities of called , which are involved in the formation of fractures. Many different bisphosphonate drugs are available, but their relative merits are uncertain.

The researchers analysed data from 20 trials involving a total of 6,692 patients who took bisphosphonate drugs including zoledronate, clodronate, pamidronate, ibandronate and etidronate in addition to their myeloma treatments. reduced the occurrence of fractures and pain. For all types of fractures, the researchers estimated that between 6 and 15 patients would need to be treated to prevent fractures in one patient. For pain, between 5 and 13 patients would need to be treated to reduce pain in one patient.

Four trials made direct comparisons between different drugs. In the remaining trials, the effects of the drugs were compared to those of placebos or no treatment and the researchers made indirect comparisons by interrogating the data from these trials. Head-to-head trials suggested that zoledronate was more effective at reducing fractures compared to etidronate, but taken together with the indirect comparisons, the researchers conclude that no one drug can be regarded as superior.

"Whether zoledronate is superior to any other bisphosphonate drug remains an open question," said lead researcher Ambuj Kumar of the Center for Evidence Based Medicine and Health Outcomes Research at the University of South Florida, in Tampa, Florida. "In light of the inconsistencies we see in the data, it is difficult to recommend any as a preferential treatment for clinical practice."

Based on the findings of the review, adverse effects of bisphosphonate drugs appear to be rare. Osteonecrosis of the jaw (a disease whereby the jaw bone can appear through lesions in the gum which do not heal) is one potential complication that has been gaining attention in recent years, but the authors report that it is no more common in those taking bisphosphonate drugs than in those receiving placebos or no treatment. "We didn't identify any significant adverse effects, but this work does highlight the need for larger head-to-head trials, which are needed to better compare the safety and effectiveness of the different drugs available," said Kumar.

Explore further: Yearly zoledronic acid at lower-than-standard doses increases bone density

More information: Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.pub3

Related Stories

Yearly zoledronic acid at lower-than-standard doses increases bone density

June 6, 2011
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic ...

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

February 8, 2012
There is growing evidence that supports an association between atypical fractures of the femur– a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.